Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity

Vaccine

Volumn 25, Issue 21, 2007, Pages 4291-4300

  Ohba, Kenji ^a,b,c   Yoshida, Shinsuke ^b   Zahidunnabi Dewan, Md ^a,b   Shimura, Hiromi ^a   Sakamaki, Nozomi ^a   Takeshita, Fumihiko ^c   Yamamoto, Naoki ^a,b   Okuda, Kenji ^c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Cytoplasmic localization; Immunogenicity; NPm

Indexed keywords

DNA BASE; DNA VACCINE; INFLUENZA VACCINE; THREONYLTYROSYLGLUTAMINYLARGINYLTHREONYLARGINYLALANYLLEUCYLVALINE; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOPLASM; DRUG SYNTHESIS; EMBRYO; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A; MALE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; VACCINATION; WILD TYPE;

ANIMALS; CROSS REACTIONS; CYTOPLASM; FLOW CYTOMETRY; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON TYPE II; MALE; MICE; MICE, INBRED BALB C; MUTATION; NUCLEOPROTEINS; RNA-BINDING PROTEINS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL CORE PROTEINS;

EID: 34247366803     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.02.074     Document Type: Article

References (41)

1. Palese P. Influenza: old and new threats. Nat Med 10 (2004) S82-S87
2. Horimoto T., and Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 3 (2005) 591-600
3. Nicholson K.G., Wood J.M., and Zambon M. Influenza. Lancet 362 (2003) 1733-1745
4. Lewis D.B. Avian flu to human influenza. Annu Rev Med 57 (2006) 139-154
5. Beigel J.H., Farrar J., Han A.M., Hayden F.G., Hyer R., de Jong M.D., et al. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in human. N Engl J Med 354 (2006) 884
6. de Jong M.D., and Hieo T.T. Avian influenza (H5N1). J Clin Virol 35 (2006) 2-13
7. Wood J.M., and Robertson J.S. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2 (2004) 842-847
8. Rimmeizwaan G.F., and Osterhaust A.D. Influenza vaccine: new developments. Curr Opin Pharmacol 1 (2001) 491-496
9. Steinhauer D.A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 258 (1999) 1-20
10. Fouchier R., Munster A.M., Wallensten V., Bestebroer A., Herfst T.M., Smith S., et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79 (2005) 2814-2822
11. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 234 2 (2005) 110-123
12. Portela A., and Digad P. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol 83 (2002) 723-734
13. Elton D., Simpson-Holley M., Archer K., Medcalf L., Hallan R., McCauley J., et al. Inetraction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J Virol 75 1 (2001) 408-419
14. Sakaguchi A., Hirayama E., Hiraki A., Ishida Y., and Kim J. Nuclear export of influenza viral ribonucleoprotein is temperature-dependently inhibited by dissociation of viral matrix protein. Virology 306 2 (2003) 244-253
15. Hung X., Liu T., Muller J., Levandowski R.A., and Ye Z. Effect of influenza virus matrix protein and viral RNA on ribonucleoprotein formation and nuclear export. Virology 287 2 (2001) 405-416
16. Bui M., Myers J.E., and Whittaker G.R. Nucleo-cytoplasmic localization of influenza virus nucleoprotein depends on cell density and phosphorylation. Virus Res 84 (2002) 37-44
17. Bullido R., Gomez-Puertas P., Albo C., and Portela A. Several protein regions contribute to determine the nuclear and cytoplasmic localization of the influenza A virus nucleoprotein. J Gen Virol 81 (2000) 135-142
18. Elton D., Medcalf L., Bishop K., Harrison D., and Digard P. Identification of amino acid residues of influenza virus nucleoprotein essential for RNA binding. J Virol 73 9 (1999) 7357-7367
19. Digard P., Elton D., Bishop K., Medcalf E., Weeds A., and Pope B. Modulation of nuclear localization of the influenza virus nucleoprotein through interaction with actin filaments. J Virol 73 3 (1999) 2222-2231
20. Neumann G., Castrucci M.R., and Kawaoka Y. Nuclear import and export of influenza virus nucleoprotein. J Virol 71 12 (1997) 9690-9700
21. Davey J., Dimmock N.J., and Colman A. Identification of the sequence responsible for the nuclear accumulation of the influenza virus nucleoprotein in Xenopus oocytes. Cell 40 (1985) 667-675
22. Hogan R.J., Usherwood E.J., Zhong W., Roberts A.A., Dutton R.W., Harmsen A.G., et al. Activated antigen-specific CD8+ T cells persisit in the lungs following recovery from respiratory virus infections. J Immunol 166 3 (2001) 1813-1822
23. Tumer S.J., Cross R., Xie W., and Doherty P.C. Concurrent naïve and memory CD8+ T cell response to an influenza A virus. J Immunol 167 5 (2001) 2753-2758
24. Wiley J.A., Hogan R.J., Woodland D.L., and Harmsen A.G. Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza infection. J Immunol 167 6 (2001) 3293-3299
25. Breathnach C.C., Clark H.J., Clark R.C., Olsen C.W., Townsend H.G., and Lunn D.P. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 24 8 (2006) 1180-1190
26. Altstein A.D., Gitelman A.K., Smirnov Y.A., Piskareva L.M., Zakharova L.G., Pashvykina G.V., et al. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol 151 5 (2006) 921-931
27. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 5102 (1993) 1745-1749
28. Kloetzel P.M. Generation of major histcompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat Immunol 5 7 (2004) 611-669
29. Golovina T.N., Wherrv E.J., Bullock T.N., and Eisenlohr L.C. Efficient and qualitatively distinct MHC class I-restricted presentation of antigen targeted to the endoplasmic reticulum. J Immunol 168 6 (2002) 2667-2675
30. Sijts A., Sun Y., Janek K., Kral S., Paschen A., Schadendorf D., et al. The role of the proteasome activator PA28 in MHC class I antigen processing. Mol Immunol 39 3-4 (2002) 165-169
31. Yamano T., Murata S., Shimbara N., Tanaka N., Chiba T., Tanaka K., et al. Two distinct pathways mediated by PA28 and hsp90 in major histocompatibility complex class I antigen processing. J Exp Med 196 2 (2002) 185-196
32. Fruci D., Lauvau G., Saveanu L., Amicosante M., Butler R.H., Polack A., et al. Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport. J Immunol 170 6 (2003) 2977-2984
33. Seifert U., Maranon C., Shmueli A., Desoutter J.F., Wesoloski L., Janek K., et al. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol 4 4 (2003) 375-379
34. Rock K.L., York I.A., and Goldberg A.L. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 5 7 (2004) 670-677
35. Kloetzel P.M. The proteasome and MHC class I antigen processing. Biochim Biophys Acta 1695 1-3 (2004) 225-233
36. Niwa K., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991) 193-196
37. Guermonprez P., and Amigorena S. Pathway for antigen cross presentation. Springer Semin Immunopathol 26 3 (2005) 257-271
38. Shen L., Sigal L.J., Boes M., and Rock K.L. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 21 2 (2004) 155-165
39. Sun Y., Sijts A.J., Song M., Janek K., Nussbaum A.K., Kral S., et al. Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Cancer Res 62 10 (2002) 2875-2882
40. Basu S., Binder R.J., Ramalingam T., and Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14 3 (2001) 303-313
41. Castellino F., Boucher P.E., Eichelberg K., Mayhew M., Rothman J.E., Houghton A.N., et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 191 11 (2000) 1957-1964